Systematic ReviewResearchPatient EducationWorkflow

Epilepsy neuromodulation showed modest mood gains without cognitive decline in a review

Acta Neurologica Belgica (PubMed)Jul 30, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A systematic review of 35 studies found a small pooled improvement in depression after chronic neuromodulation for drug-resistant epilepsy, while cognitive performance remained largely stable across vagus nerve, deep brain, and responsive neurostimulation modalities.

What NurseJet pulled from the source

Twenty-four studies contributed to meta-analysis, representing 2,418 patients followed for six months to 14 years. The pooled depression effect was small, vagus nerve stimulation had the largest subgroup signal, and quality of life improved over time. Neuropsychiatric adverse events were most frequent early with anterior thalamic deep brain stimulation.

Why this matters for nurses

Neurology nurses assess mood, cognition, behavior, seizure burden, device tolerance, and caregiver concerns throughout neuromodulation follow-up. Stable group-level cognitive findings do not replace individual surveillance for new psychiatric or cognitive symptoms.

Bedside takeaway

Neuromodulation was associated with modest mood gains and stable group-level cognition, but individual monitoring remains essential.

How This Applies in Practice

Use this when: Assessing an adult or child with drug-resistant epilepsy before or during chronic neuromodulation follow-up.

On your shift

Document baseline and interval mood, cognition, behavior, seizure burden, device tolerance, and caregiver observations.
Use the approved screening and escalation pathway for suicidal thinking, marked mood change, cognitive decline, or seizure worsening.
Reinforce device-specific safety, follow-up, and emergency instructions with the patient and caregiver using teach-back.

Keep in mind: Group-level stability does not rule out individual neuropsychiatric adverse effects, and modalities were not directly compared. Follow the neurology protocol, facility policy, and provider orders.

Key takeaways

The review included 35 studies, with 24 studies and 2,418 patients contributing to quantitative synthesis.
Depression scores showed a small pooled improvement after chronic neuromodulation.
Overall cognitive performance did not show a significant decline across the three modalities.
Anterior thalamic deep brain stimulation had the most frequent reported neuropsychiatric adverse events, particularly early in follow-up.

Practice implications

At baseline and follow-up, use the approved mood, cognition, seizure, and device-assessment workflow; compare changes with the patient's usual function and caregiver observations. Escalate suicidal thinking, marked mood or behavior change, cognitive decline, seizure worsening, or device concerns promptly.

Limitations & cautions

The included studies varied by neuromodulation modality, design, outcome measure, and follow-up duration, and subgroup findings do not prove one device is superior. Pooled group averages may obscure individual adverse effects, and the abstract does not provide certainty ratings for each outcome.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Acta Neurologica Belgica (PubMed)

Acta Neurologica Belgica (PubMed). Long-term neuropsychiatric outcomes after neuromodulation in epilepsy patients: a systematic review and meta-analysis.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42530840/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Pediatric emergency care (PubMed)Sep 7, 2026Research Article

A double-blind randomized trial found no reduction in vomiting or faster oral tolerance with intravenous pantoprazole versus placebo in children with acute gastroenteritis and persistent vomiting after ondansetron.

Peds EmergencyAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 100 children. Vomiting episodes and oral tolerance at 6 and 12 hours did not differ significantly, while median hospital stay was 2 days with pantoprazole and 1 day with placebo.

Key takeaways

The median participant age was 14 months, and 67% of participants were male.
Oral tolerance at 12 hours was 86% in both groups.
The longer stay associated with pantoprazole requires cautious interpretation because this was a single-center trial.

Why this matters on shift

The trial does not support empiric intravenous proton-pump inhibition for persistent vomiting in pediatric acute gastroenteritis after ondansetron.

Bedside takeaway

Clarify the indication for empiric acid suppression and keep hydration and oral-tolerance assessment central to care.

Nursing implications

Prioritize the ordered hydration and oral-tolerance plan, document ongoing emesis, and clarify the indication before administering empiric acid suppression.

Limitations & cautions

Abstract-only summary. This was a single-center study of 100 children in Tehran, and the abstract does not describe adverse events or explain why hospitalization was longer in the pantoprazole group.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Pediatric emergency care (PubMed). Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of neurosurgical anesthesiology (PubMed)Sep 4, 2026Research Article

A five-center randomized trial found similar rescue-opioid use and moderate-to-severe PACU pain with dexmedetomidine-based opioid-sparing analgesia and fentanyl-based analgesia during elective craniotomy for brain tumors.

Emergency ICUAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 500 adults. Moderate-to-severe PACU pain occurred in 145 of 242 assessed participants in the fentanyl group and 138 of 233 in the dexmedetomidine group, with no significant difference.

Key takeaways

Intraoperative rescue fentanyl use did not differ significantly between groups.
Hypotension was more common with dexmedetomidine, while postoperative shivering was less common.
Other in-hospital outcomes were similar between the two regimens.

Why this matters on shift

An opioid-sparing label did not translate into better early pain control in this trial, and the differing hypotension and shivering profiles remain relevant during perioperative handoff and recovery monitoring.

Bedside takeaway

Monitor pain, hemodynamics, sedation, and shivering in relation to the analgesic regimen and local protocol.

Nursing implications

During PACU and postoperative handoff, monitor pain, hemodynamics, sedation, and shivering according to the administered regimen and local protocol.

Limitations & cautions

Abstract-only summary. The trial involved elective tumor craniotomy at five Indian centers, both groups also received locoregional analgesia, and the abstract does not provide longer-term outcome results in detail.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of neurosurgical anesthesiology (PubMed). Opioid-Sparing Versus Opioid-Based Analgesia for Craniotomy: A Multicenter Randomized Controlled Trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

BMC geriatrics (PubMed)Sep 5, 2026Research Article

A multicountry emergency-department analysis found that older patients' presenting complaints did not by themselves reflect underlying severity or disposition risk.

Emergency GeriatricsAI summaryReview source

Research ArticleResearchNew Grad FriendlyAI summary · original source linked below

The analysis included 2,794 adults aged 65 or older with one non-traumatic chief complaint across 36 emergency departments in nine European countries. Shortness of breath was associated with threefold admission odds and 2.2-fold in-hospital mortality odds.

Key takeaways

Shortness of breath, abdominal pain, chest pain, weakness or fatigue, and extremity symptoms accounted for 59% of presentations.
Age 85 or older, geriatric risk factors, polypharmacy, and shortness of breath were associated with admission.
The authors called for structured evaluation, staff training, and geriatric-specific care pathways.

Why this matters on shift

A seemingly routine complaint can coexist with frailty, polypharmacy, cognitive impairment, or other risks that change emergency assessment and disposition planning.

Bedside takeaway

Pair the presenting complaint with structured geriatric, medication, cognitive, functional, and physiologic assessment.

Nursing implications

Pair the chief complaint with structured geriatric, medication, cognitive, functional, and physiologic assessment using local emergency protocols.

Limitations & cautions

Abstract-only summary. This was a secondary observational analysis of seven-day samples collected during the 2020 COVID-19 pandemic; associations do not prove causation and may not generalize to all emergency settings.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

BMC geriatrics (PubMed). Non-traumatic chief complaints in older patients in European emergency departments and associated outcomes during the Covid-19 pandemic - a secondary analysis of the cross sectional EGERS study.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

IV pantoprazole did not improve vomiting or oral tolerance in pediatric gastroenteritis

Dexmedetomidine did not improve early pain outcomes versus fentanyl for craniotomy

Chief complaint alone did not capture risk in older emergency patients